Erratum to "Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents" [Gynecol. Oncol. 115 (2009) 438-442] (DOI:10.1016/j.ygyno.2009.09.007);Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents

Gynecologic Oncology

Volumn 115, Issue 3, 2009, Pages 438-442

  Moxley, Katherine Marie ^a   Chengedza, Shylet ^a   Mangiaracina, Doris ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Flexible heteroarotinoid (Flex Het); Ovarian cancer; SHetA2; TNF related apoptosis inducing ligand (TRAIL); Tumor necrosis factor alpha (TNF )

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CISPLATIN; DEATH RECEPTOR; FLEXIBLE HETEROAROTINOID COMPOUND; LIGAND; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVATION; EPITHELIAL OVARY CARCINOMA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OVARY CARCINOMA; OVARY CELL; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CHROMANS; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; RECOMBINANT PROTEINS; THIONES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350567239     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.02.026     Document Type: Erratum

References (31)

1. 32P or intravenous cyclophosphamide and cisplatin - a gynecologic oncology group study. J. Clin. Oncol. 21 23 (2003) 4350-4355
2. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 21 17 (2003) 3194-3200
3. Bookman M.A., Brady M.F., McGuire W.P., Harper P.G., Alberts D.S., Friedlander M., et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol. 27 9 (2009) 1355-1358
4. Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E., et al. p53 status and the efficacy of cancer therapy in vivo. Science 266 (1994) 807-810
5. Fulda S., and Debatin K.M. Targeting apoptosis pathways in cancer therapy. Curr. Cancer Drug Targets 4 7 (2004 Nov) 569-576
6. Fulda S., and Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25 34 (2006 Aug 7) 4798-4811
7. Szlosarek P.W., and Balkwill F.R. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 4 9 (2003 Sep) 565-573
8. Titia E., Lans D.L.B., Libutti S.K., Gnant M.F.X., Liewehr D.J., Venzon D.J., et al. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion1. Clin. Cancer Res. 7 (2001, April) 784-790
9. Hao Wu J.T., and Lin S.C. Smac mimetics and TNFa: a dangerous liaison?. Cell 131 (2007, November 16) 655-658
10. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155-162
11. Takeda K., Stagg J., Yagita H., Okumura K., and Smyth M.J. Targeting death-inducing receptors in cancer therapy. Oncogene 26 (2007) 3745-3757
12. Oldenhuis C.N.A.M., Stegehuis J.H., Walenkamp A.M.E., de Jong S., and de Vries E.G.E. Targeting TRAIL death receptors. Curr. Opin. Pharmacol. 8 4 (2008, Aug) 433-439
13. Johnstone R.W., Frew A.J., and Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev., Cancer 8 (2008) 782-798
14. Dong H.P., Kleinberg L., Silins I., Florenes V.A., Trope C.G., Risberg B., et al. Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian cancer. Cancer 112 (2008) 84-93
15. Benbrook D.M., Kamelle S.A., Guruswamy S.B., Lightfoot S.A., Hannafon B., Rutledge T.L., et al. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor antagonists. Inv. New Drugs 23 (2005) 417-428
16. Benbrook D.M., Lightfoot S., Ranger-Moore J., Liu T., Chengedza S., Berry W.L., et al. Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention. Gene Regul. Syst. Biol. 2 (2008) 21-42
17. Guruswamy S., Lightfoot S., Gold M., Hassan R., Berlin K.D., Ivey R.T., et al. Effects of retinoids on cancerous phenotype and apoptosis in organotypic culture of ovarian carcinoma. J. Nat. Cancer Inst. 93 (2001) 516-525
18. Myers T, Chengedza S, Lightfoot S, Pan Y, Dedmond D, Cole L, et al. Flexible Heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Investigational New Drugs. 2008: published online: 18 September.
19. Liu T., Masamha P., Chengedza S., Berlin K.D., Lightfoot S., He F., et al. Development of flexible-heteroarotinoids (Flex-Hets) for kidney cancer. Mol. Cancer Ther. 8 5 (2009) 1227-1238
20. Liu T.Z., Hannafon B., Gill L., Kelly B., and Benbrook D.M. Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Mol. Cancer Ther. 6 (2007) 1814-1822
21. Liu S., Brown C.W., Berlin K.D., Dhar A., Guruswamy S.B., Brown D., et al. Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J. Med. Chem. 47 (2004) 999-1007
22. Kamelle S.A., Sienko A., and Benbrook D.M. Retinoids and steroids regulate menstrual phase histologic features in human endometrial organotypic cultures. Fertil. Steril. 78 3 (2002) 596-602
23. Kim Y.H., and Lee Y.J. Time sequence of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin treatment is responsible for a complex pattern of synergistic cytotoxicity. J. Cell. Biochem. 98 (2006) 1284-1295
24. Diessenbacher P., Hupe M., Sprick M.R., Kerstan A., Geserick P., Haas T.L., et al. NF-kappaB inhibition reveals differential mechanisms of TNF versus TRAIL-induced apoptosis upstream or at the level of caspase-8 activation independent of cIAP2. J. Invest. Dermatol. 128 5 (2008 May) 1134-1147
25. Le T.C., Berlin K.D., Benson S.D., Eastman M.A., Bell-Eunice G., Nelson A.C., et al. Heteroarotinoids with anti-cancer activity against ovarian cancer cells. Open. Med. Chem. J. 1 (2007) 11-23
26. Mic F.A., Molotkov A., Benbrook D.M., and Duester G. Retinoid activation of retinoic acid receptor but not retinoid X receptor is sufficient to rescue lethal defect in retinoic acid synthesis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 7135-7140
27. Shamimi-Noori S., Yeow W.S., Ziauddin M.F., Xin H., Tran T.L.N., XIe J., et al. Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway. Cancer Gene Ther. 15 (2008) 356-370
28. Shanhar S., Chen X., and Srivastava R.K. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 62 2 (2005) 165-186
29. Singh T.R., Shankar S., Chen X., Asim M., and Srivastava R.K. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. 63 17 (2003) 5390-5400
30. Kim M., Liao J., Dowling M.L., Voong K.R., Parker S.E., Wang S., et al. TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells. Cancer Res. 68 9 (2008, May 1) 3440-3449
31. Kim M., Liao J.D., Voong M.L., Parker K.R., Wang S.E., El-Deiry S., W.S, et al. TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells. Cancer Res 68 9 (2008) 3440-3449